Compare Williams-Sonoma, Inc. (WSM) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Williams-Sonoma, Inc. vs State Street SPDR S&P Biotech ETF — how do they compare? Williams-Sonoma, Inc. trades at $228.08 (market cap $26.83B), while State Street SPDR S&P Biotech ETF trades at $159.93. The key difference: Williams-Sonoma, Inc. pays a 1.33% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Williams-Sonoma, Inc. nearer its low. Which is the better fit depends on your goals.
| WSM | XBI | |
|---|---|---|
Market Cap | $26.83B | — |
Sector | Consumer Cyclical | Broad Market / Factor |
52-Week High | $251.81 | $169.55 |
52-Week Low | $168.64 | $93.43 |
Enterprise Value | $27.33B | — |
Dividend Yield | 1.33% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Williams-Sonoma (WSM) trades at $227.83, up 0.18% on the day, with a bearish technical signal but strong fundamentals. The stock has beaten earnings estimates for three consecutive quarters, with Q2 2026 EPS of $2.10 exceeding expectations. Revenue growth of 6.2% in Q2 2026 reflects market share gains in a flat home furnishings industry, supported by a robust net income margin of 14.73% and ROE of 54.96%.
The outlook is positive given raised full-year guidance and analyst consensus price target of $252.62, though near-term risks include tariff pressures on margins and technical resistance near $231. Institutional buying, such as HSBC's 12.1% stake increase in Q2 2026, underscores confidence in continued execution amid competitive and macroeconomic headwinds.
XBI trades at $161.97, down 1.12% today, with technical indicators showing mixed signals amid a bearish overall trend. The ETF holds over 150 biotech companies and has rallied 76% in the past year, driven by M&A activity and positive clinical trial catalysts. Analyst coverage remains limited with a single hold rating, while recent news highlights sector optimism around cancer vaccine breakthroughs and improved capital access.
Outlook remains cautiously optimistic with potential for 8-14% returns over 6-12 months, though high volatility and regulatory risks persist. Key opportunities include ongoing pharmaceutical M&A and innovation in immunotherapy, while risks center on sector-specific volatility and policy uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Williams-Sonoma, Inc.
With a wide retail and direct-to-consumer presence, Williams-Sonoma is a leader in the $300 billion domestic home category, focused on expanding its exposure in the B2B, marketplace, and franchise areas. Namesake Williams-Sonoma (175 stores) offers high-end cooking essentials, while Pottery Barn (189) provides casual home accessories. Brand extensions include Pottery Barn Kids (52) and PBteen. West Elm (121) is an emerging concept for young professionals, and Rejuvenation (9) offers lighting and house parts. Williams-Sonoma also has a business-to-business team that supports projects that range from residential to large-scale commercial.
Read more on WSM →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
